These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3489205)

  • 1. [Experimental model of Parkinson disease induced by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
    Renkawek K
    Neuropatol Pol; 1986; 24(1):1-8. PubMed ID: 3489205
    [No Abstract]   [Full Text] [Related]  

  • 2. Study on MPTP-induced parkinsonian animal model in rhesus monkey and the mechanism of MPTP.
    Chen SD; Xu DL; Yu HZ; Tang QM; Xu XR; Wang ZG; Liang PF
    Chin Med J (Engl); 1988 Dec; 101(12):879-83. PubMed ID: 3150735
    [No Abstract]   [Full Text] [Related]  

  • 3. MPTP in animal models of Parkinson's disease.
    Kopin IJ; Schoenberg DG
    Mt Sinai J Med; 1988 Jan; 55(1):43-9. PubMed ID: 3126391
    [No Abstract]   [Full Text] [Related]  

  • 4. The MPTP story: an introduction.
    Marsden CD; Sandler M
    J Neural Transm Suppl; 1986; 20():1-3. PubMed ID: 3091759
    [No Abstract]   [Full Text] [Related]  

  • 5. [MPTP and Parkinson's disease].
    Imai H
    No To Shinkei; 1988 Nov; 40(11):1011-24. PubMed ID: 3064783
    [No Abstract]   [Full Text] [Related]  

  • 6. [Experimental parkinsonian syndrome in rats induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine].
    Kryzhanovskiĭ GN; Atadzhanov MA; Zagorevskiĭ VA; Sharkova LM; Voronina TA
    Biull Eksp Biol Med; 1988 Apr; 105(4):397-401. PubMed ID: 3258764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary (toxic) parkinsonism as model of Parkinson's disease.
    Riederer P; Sofic E; Heuschneider G; Benedetti MS; Dostert P
    Funct Neurol; 1988; 3(4):449-57. PubMed ID: 3072280
    [No Abstract]   [Full Text] [Related]  

  • 8. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): one designer drug and serendipity.
    Weingarten HL
    J Forensic Sci; 1988 Mar; 33(2):588-95. PubMed ID: 3259617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simple quantitative bradykinesia test in MPTP-treated mice.
    Ogawa N; Hirose Y; Ohara S; Ono T; Watanabe Y
    Res Commun Chem Pathol Pharmacol; 1985 Dec; 50(3):435-41. PubMed ID: 3878557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MPTP-induced parkinsonism. Recent studies on the mechanism of toxicity.
    Bocchetta A; Piccardi MP; Zuddas A; Bernardi F; Zompo MD; Corsini GU
    Funct Neurol; 1988; 3(4):439-47. PubMed ID: 3072279
    [No Abstract]   [Full Text] [Related]  

  • 11. The MPTP model of Parkinson's disease.
    Smeyne RJ; Jackson-Lewis V
    Brain Res Mol Brain Res; 2005 Mar; 134(1):57-66. PubMed ID: 15790530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey.
    Chiueh CC; Markey SP; Burns RS; Johannessen JN; Jacobowitz DM; Kopin IJ
    Psychopharmacol Bull; 1984; 20(3):548-53. PubMed ID: 6332333
    [No Abstract]   [Full Text] [Related]  

  • 13. [Parkinsonism and MPTP (methylphenyltetrahydropyridine)].
    Nagatsu T
    No To Shinkei; 1986 Jul; 38(7):706-7. PubMed ID: 3489476
    [No Abstract]   [Full Text] [Related]  

  • 14. [Mechanism of induction of parkinsonism by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a dopaminergic neurotoxin].
    Hirata Y; Nagatsu T
    Tanpakushitsu Kakusan Koso; 1986 Apr; 31(5):398-409. PubMed ID: 3520683
    [No Abstract]   [Full Text] [Related]  

  • 15. Endogenous analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: indoleamine derived tetrahydro-beta-carbolines as potential causative factors in Parkinson's disease.
    Collins MA; Neafsey EJ; Cheng BY; Hurley-Gius K; Ung-Chhun NA; Pronger DA; Christensen MA; Hurley-Gius D
    Adv Neurol; 1987; 45():179-82. PubMed ID: 3493625
    [No Abstract]   [Full Text] [Related]  

  • 16. MPTP and the aetiology of Parkinson's disease. Clinical implications. London, June 27, 1985.
    J Neural Transm Suppl; 1986; 20():1-81. PubMed ID: 3489069
    [No Abstract]   [Full Text] [Related]  

  • 17. MPTP: current concepts and controversies.
    Langston JW; Irwin I
    Clin Neuropharmacol; 1986; 9(6):485-507. PubMed ID: 3542203
    [No Abstract]   [Full Text] [Related]  

  • 18. [MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and parkinsonism].
    Gao XM; Ku BS
    Sheng Li Ke Xue Jin Zhan; 1989 Apr; 20(2):161-3. PubMed ID: 2686017
    [No Abstract]   [Full Text] [Related]  

  • 19. [Parkinsonism and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (review of the literature)].
    Atadzhanov MA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1991; 91(4):117-21. PubMed ID: 1650080
    [No Abstract]   [Full Text] [Related]  

  • 20. Changes in the local cerebral metabolic rate for glucose in the MPTP primate model of Parkinson's disease.
    Schwartzman RJ; Alexander GM
    Adv Neurol; 1987; 45():171-3. PubMed ID: 3493624
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.